THERAPY DOSSIER · th-b6afda76c8b6

Phycocyanin

Nutraceutical · Phycocyanin, a blue phycobiliprotein pigment from cyanobacteria/spirulina.

Evidence & regulatory context

Mechanism: Phycocyanin, a blue phycobiliprotein pigment from cyanobacteria/spirulina.
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT07013890 ↗PHASE4completed

Phycocyanin + Palmitoylethanolamide in Chronic Prostatitis/CPPS

Chronic Prostatitis

Enrolment: 48 · Results not recorded

NCT07271576 ↗NArecruiting

Phycocyanin in Prevention and Treatment of Liver Fibrosis/Cirrhosis

Liver Fibrosis · Liver Cirrhosis

Enrolment: 10 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32739742 ↗2020Reported benefit

Therapeutic effect of phycocyanin on acute liver oxidative damage caused by X-ray.

MouseRadiationC57BL/6MaleOral gavage200 mg/kgGiven for 7 consecutive days either before or after irradiation

Model: X-ray radiation-induced acute liver oxidative damage

Phycocyanin given before or after irradiation lowered plasma ALT and AST, reduced hepatic ROS and DNA damage and upregulated Nrf2/HO-1 antioxidant signalling.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…